← Back to Search

Cryo Biopsy/Ablation for Lung Disease (CT0129 Trial)

N/A

Recruiting

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients undergoing lung transplant surgery

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 48 months

Awards & highlights

CT0129 Trial Summary

This trial tests a new tool for removing or destroying abnormal growths in the lungs.

Who is the study for?

This trial is for patients who are undergoing lung transplant surgery. It's not open to individuals who can't donate their lungs or those who are healthy without any lung disease.Check my eligibility

What is being tested?

The study is testing a new technique using cryogenic catheters for biopsy and treatment of lung lesions, aiming to establish a standard method in an ex-vivo (outside the body) human lung model.See study design

What are the potential side effects?

Since this is an ex-vivo study, meaning it's conducted on lungs outside the body, there aren't direct side effects like those seen in living patients.

CT0129 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for or have had a lung transplant.

CT0129 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 48 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~48 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Freezing Time

Measure of Pleural breakage (Absent or Present)

Model of cryogen

+2 more

Secondary outcome measures

Blood loss and complication

CT0129 Trial Design

1Treatment groups

Experimental Treatment

Group I: Ex Vivo CryoExperimental Treatment1 Intervention

Multiple procedures will be performed to each model in order to accomplish the objectives of the study. Tissue samples will be taken from the models and images will be performed. This will allow us to determine which configuration is the optimal for obtaining the more effective and stable models that could offer the best quality specimens as well.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

129,437 Total Patients Enrolled

Media Library

Ex Vivo Cryo Clinical Trial Eligibility Overview. Trial Name: NCT05948904 — N/A

Lung Disease Research Study Groups: Ex Vivo Cryo

Lung Disease Clinical Trial 2023: Ex Vivo Cryo Highlights & Side Effects. Trial Name: NCT05948904 — N/A

Ex Vivo Cryo 2023 Treatment Timeline for Medical Study. Trial Name: NCT05948904 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this experiment have vacancies for potential participants?

"Data from clinicaltrials.gov suggests that this trial, posted on August 1st 2023 and last updated July 10th 2023 is not currently enrolling patients; however there are 296 other options for individuals seeking to participate in a medical study at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study.

2023. "Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05948904.

All > Lung Disease